What does BRUPHARMA do?

BRUPHARMA is a pharmacy in Ganshoren. Public Limited, started on 3 March 1997, 1 establishment.

What is the address of BRUPHARMA?

The registered office of BRUPHARMA is located at Margaretha van Oostenrijkplein 3, 1083 Ganshoren.

Is BRUPHARMA still active?

Yes. According to the CBE (30 October 2026) BRUPHARMA is active, legal situation “Normale toestand”, started on 3 March 1997.

Is BRUPHARMA registered on Peppol?

Yes, BRUPHARMA is registered on the Peppol network with ID 0208:0460143947.

What is the enterprise number of BRUPHARMA?

The enterprise number of BRUPHARMA is BE0460143947.

When was BRUPHARMA founded?

BRUPHARMA was founded on 3 March 1997.

Who are the directors of BRUPHARMA?

According to the 2024 annual accounts, the directors of BRUPHARMA are: Brupharma NV.

Is BRUPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 3 March 1997; 4 annual accounts filed, latest fiscal year 2024; 1 directors known from the annual account.

How much profit did BRUPHARMA make in 2024?

BRUPHARMA posted a profit after taxes of € 23,906 in financial year 2024.

What is the revenue of BRUPHARMA?

As a small company, BRUPHARMA is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 461,304.

How much does an employee at BRUPHARMA earn?

The average wage cost per full-time employee at BRUPHARMA was € 81,100 in 2024: staff costs of € 397,487 for 4.9 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does BRUPHARMA have?

According to the 2024 annual accounts, BRUPHARMA has 4.9 full-time equivalents (FTE).

BRUPHARMA (Public Limited) - Ganshoren - BE0460143947

Dossier BRUPHARMA, printed on 30 October 2026 from databakkes.be/en/0460143947/brupharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Tight liquidity NBB

Cash and receivables cover 35 % of short-term debt in 2024; threshold 65 %.

Financials

Financial year 2024

BRUPHARMA from Ganshoren, company number BE0460143947, closed financial year 2024 with a result of € 23,906 after tax. For that financial year BRUPHARMA recorded a gross margin of € 461,304 and equity of € -46,276. Compared with financial year 2023, the result moved from € -14,290 to € 23,906. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2025.

What it is worth Caution

€ -46,276

▲ € 23,906 vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 23,906

▲ still € 14,290 loss in 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 43,195

▼ 53% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2024. Retained profit grew to € -108,250.

People and assets in 2024

Full-time equivalents

4.9

▲ 0.2 vs 2023

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 397,487

▲ 6% vs 2023

€ 81,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 12,068

▼ 21% vs 2023

Book value of vehicles, furniture and equipment.

Debts at end 2024

Bank debt ≈ 8 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 199,853

▼ 13% vs 2023

€ 23,690 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 286,780

▼ 12% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 45,060

▼ 59% vs 2023

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ 452,931 Gross margin 2021: € 452,931 First fiscal year in the series	€ 437,842 Gross margin 2022: € 437,842 ▼ 3% vs 2021 (€ 452,931) Unfavourable step	€ 384,925 Gross margin 2023: € 384,925 ▼ 12% vs 2022 (€ 437,842) Unfavourable step	€ 461,304 Gross margin 2024: € 461,304 ▲ 20% vs 2023 (€ 384,925) Favourable step	▲ 20%
Profit after taxes	€ 46,619 Profit after taxes 2021: € 46,619 First fiscal year in the series	€ 58,202 Profit after taxes 2022: € 58,202 ▲ 25% vs 2021 (€ 46,619) Favourable step	€ -14,290 Profit after taxes 2023: € -14,290 ▼ € 72,493 vs 2022 (€ 58,202) Unfavourable step	€ 23,906 Profit after taxes 2024: € 23,906 ▲ € 38,196 vs 2023 (€ -14,290) Favourable step	▲ € 38,196
Equity	€ -114,094 Equity 2021: € -114,094 First fiscal year in the series	€ -55,892 Equity 2022: € -55,892 ▲ € 58,202 vs 2021 (€ -114,094) Favourable step	€ -70,182 Equity 2023: € -70,182 ▼ € 14,290 vs 2022 (€ -55,892) Unfavourable step	€ -46,276 Equity 2024: € -46,276 ▲ € 23,906 vs 2023 (€ -70,182) Favourable step	▲ € 23,906
Total debts	€ 867,328 Total debts 2021: € 867,328 First fiscal year in the series	€ 863,328 Total debts 2022: € 863,328 Unchanged (€ 867,328) Favourable step	€ 818,039 Total debts 2023: € 818,039 ▼ 5% vs 2022 (€ 863,328) Favourable step	€ 773,792 Total debts 2024: € 773,792 ▼ 5% vs 2023 (€ 818,039) Favourable step	▼ 5%
Cash	€ 112,697 Cash 2021: € 112,697 First fiscal year in the series	€ 181,055 Cash 2022: € 181,055 ▲ 61% vs 2021 (€ 112,697) Favourable step	€ 91,860 Cash 2023: € 91,860 ▼ 49% vs 2022 (€ 181,055) Unfavourable step	€ 43,195 Cash 2024: € 43,195 ▼ 53% vs 2023 (€ 91,860) Unfavourable step	▼ 53%
Land & buildings	€ 259,929 Land & buildings 2021: € 259,929 First fiscal year in the series	€ 248,481 Land & buildings 2022: € 248,481 ▼ 4% vs 2021 (€ 259,929) Unchanged	€ 237,034 Land & buildings 2023: € 237,034 ▼ 5% vs 2022 (€ 248,481) Unchanged	€ 225,586 Land & buildings 2024: € 225,586 ▼ 5% vs 2023 (€ 237,034) Unchanged	▼ 5%
Retained profit	€ -176,068 Retained profit 2021: € -176,068 First fiscal year in the series	€ -117,865 Retained profit 2022: € -117,865 ▲ € 58,202 vs 2021 (€ -176,068) Favourable step	€ -132,156 Retained profit 2023: € -132,156 ▼ € 14,290 vs 2022 (€ -117,865) Unfavourable step	€ -108,250 Retained profit 2024: € -108,250 ▲ € 23,906 vs 2023 (€ -132,156) Favourable step	▲ € 23,906
Dividend	€ 25,000 Dividend 2021: € 25,000 First fiscal year in the series	€ 0 Dividend 2022: € 0 ▼ 100% vs 2021 (€ 25,000) Unchanged	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 246,985 Bank debt 2021: € 246,985 First fiscal year in the series	€ 229,567 Bank debt 2022: € 229,567 ▼ 7% vs 2021 (€ 246,985) Favourable step	€ 229,472 Bank debt 2023: € 229,472 Unchanged (€ 229,567) Favourable step	€ 199,853 Bank debt 2024: € 199,853 ▼ 13% vs 2023 (€ 229,472) Favourable step	▼ 13%
Balance sheet total	€ 753,234 Balance sheet total 2021: € 753,234 First fiscal year in the series	€ 807,436 Balance sheet total 2022: € 807,436 ▲ 7% vs 2021 (€ 753,234) Unchanged	€ 747,856 Balance sheet total 2023: € 747,856 ▼ 7% vs 2022 (€ 807,436) Unchanged	€ 727,515 Balance sheet total 2024: € 727,515 ▼ 3% vs 2023 (€ 747,856) Unchanged	▼ 3%
Employees (FTE)	5.8 Employees (FTE) 2021: 5.8 First fiscal year in the series	4.5 Employees (FTE) 2022: 4.5 ▼ 1.3 vs 2021 (5.8) Unchanged	4.7 Employees (FTE) 2023: 4.7 ▲ 0.2 vs 2022 (4.5) Unchanged	4.9 Employees (FTE) 2024: 4.9 ▲ 0.2 vs 2023 (4.7) Unchanged	▲ 0.2

Key figures of BRUPHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to BRUPHARMA?

What happened at BRUPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2029 Brupharma NV stepped down as director. NBB
Jun 5, 2025 New annual accounts for financial year 2024: profit of € 23,906. Source: NBB ↗
2023 Brupharma NV became a director. NBB
Aug 27, 1997 New establishment in Ganshoren. KBO
Mar 3, 1997 Start of the company according to the CBE. KBO

In short

From € 46,619 profit in 2021 to € 23,906 profit in 2024.

Paid € 32,063 in corporate taxes since 2021.

Best year ever: 2022, with € 58,202 profit.

On average € 94,100 of value added per employee in 2024.

Original PDFs at the National Bank ↗

Management

TWEE-DE 99%

The stake of TWEE-DE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

BRUPHARMA

The shares are held by TWEE-DE (99%).

Directors

According to the 2024 annual accounts

Brupharma NV

Director · represented by Peter Develter

Also active at: ALSEMPHARMA

since 2023 · until 2029

Shareholders

TWEE-DE

99%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Margaretha van Oostenrijkplein 3

1083 Ganshoren

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0460.143.947

VAT number

BE 0460.143.947

Registered office

Margaretha van Oostenrijkplein 3, 1083 Ganshoren

Names & denominations

BRUPHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

3 March 1997

Peppol

Active · Active since 1 Jan 2001

Contact

[email protected]

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

BRUPHARMA

Warning lights

Financials

What happened to BRUPHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions